CELLCEUTIX, Inc. (NASDAQOTH:CTIX)

CAPS Rating: 1 out of 5

Results 1 - 8 of 8

Recs

0
Member Avatar pchop12316 (75.74) Submitted: 12/17/2014 9:58:19 PM : Underperform Start Price: $4.32 CTIX Score: +4.00

good short

Recs

0
Member Avatar MMCapitalMgmt (99.82) Submitted: 12/3/2014 11:39:18 AM : Underperform Start Price: $3.44 CTIX Score: -22.52

lol

Recs

2
Member Avatar zzlangerhans (99.85) Submitted: 12/2/2014 11:26:09 PM : Underperform Start Price: $3.30 CTIX Score: -27.53

It's not easy to keep up with all the scams and cons in biopharma these days but every once in a while my kids actually go to sleep and don't wake up an hour later, and I have to make the most of it. Cellceutix is a fun one for several reasons, not the least of which is my interaction with a group of pumpers on SA who might or might not be affiliated with the company.

Despite their claims of billion dollar markets for their two original developmental drugs, Kevetrin and Prurisol, Cellceutix felt it necessary to acquire Polymedix's antibiotic Brilacidin out of bankruptcy court for a pittance. In October, the company claimed positive results from a phase IIb trial of Brilacidin vs Cubicin for skin infections. Nevertheless, they don't seem eager to proceed with phase III trials for that indication, opting instead for a phase II trial for oral mucositis. It's hard to imagine Brilacidin becoming a commercially successful drug when Polymedix couldn't leverage it to keep themselves out of bankruptcy, and no other pharma such as Cubist made any attempt to pick it up. Incredibly, Kevetrin is still being tested in a phase I dose escalation trial that was initiated more than two years ago. Cellceutix plans to meet with the FDA regarding a phase II/III trial of Prurisol for psoriasis, despite having aborted plans for a proof of concept trial. Why did they decide not to seek proof of concept? No one knows.

As always, Cellceutix is a cash anaerobe subsisting on continuous ATM's. Among other red flags are significant concerns about the capital structure, with a heavy concentration of preferred stock options in the hands of the two company founders, who at one point were the only employees. The ascent of the stock since August has been impressive but I believe the eventual depressing outcome is inevitable.

Recs

0
Member Avatar SmartAce (99.87) Submitted: 9/22/2014 3:57:41 PM : Underperform Start Price: $2.33 CTIX Score: -78.18

Yo 148, 3-to-the-3-to-the-6-to-the-9.

Recs

0
Member Avatar eyezie1 (53.77) Submitted: 4/9/2014 2:47:04 AM : Outperform Start Price: $1.57 CTIX Score: +157.12

Brilacidin is a competitor of Cubist and Durata for use in gram positive infections. FDA is fast tracking antibiotics.

Recs

0
Member Avatar adi101 (82.15) Submitted: 3/2/2014 7:45:11 AM : Outperform Start Price: $1.95 CTIX Score: +104.06

clinical stage, 3 drugs in development: new antibiotic, anti psoriasis, cancer drug.

Recs

0
Member Avatar kmac28 (< 20) Submitted: 12/9/2013 6:49:02 AM : Outperform Start Price: $1.62 CTIX Score: +146.25

Fully dependent on current FDA trials at Dana Farber Cancer institute in MA.

Recs

0
Member Avatar jed71 (86.73) Submitted: 9/12/2013 11:38:55 AM : Underperform Start Price: $1.97 CTIX Score: -91.46

Pump N Dump scam.

Results 1 - 8 of 8

Featured Broker Partners


Advertisement